Drug Profile
PV 705
Latest Information Update: 21 Aug 2003
Price :
$50
*
At a glance
- Originator International Diabetes Institute
- Developer GroPep; International Diabetes Institute
- Class
- Mechanism of Action Intercellular signalling peptide and protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic neuropathies
Most Recent Events
- 28 Mar 2002 Discontinued - Phase-II for Diabetic neuropathies in Australia (Topical)
- 18 Jul 2001 Phase-II clinical trials for Diabetic neuropathies in Australia (Topical)